CN101346375A - 调节门离子通道用组合物和方法 - Google Patents
调节门离子通道用组合物和方法 Download PDFInfo
- Publication number
- CN101346375A CN101346375A CNA2006800440109A CN200680044010A CN101346375A CN 101346375 A CN101346375 A CN 101346375A CN A2006800440109 A CNA2006800440109 A CN A2006800440109A CN 200680044010 A CN200680044010 A CN 200680044010A CN 101346375 A CN101346375 A CN 101346375A
- Authority
- CN
- China
- Prior art keywords
- isoquinoline
- pyrrolo
- alkyl
- phenyl
- tetrahydrochysene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Description
Claims (98)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73960005P | 2005-11-23 | 2005-11-23 | |
US60/739,600 | 2005-11-23 | ||
PCT/CA2006/001897 WO2007059608A1 (en) | 2005-11-23 | 2006-11-22 | Compositions and methods for modulating gated ion channels |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101346375A true CN101346375A (zh) | 2009-01-14 |
CN101346375B CN101346375B (zh) | 2013-04-10 |
Family
ID=38066867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800440109A Expired - Fee Related CN101346375B (zh) | 2005-11-23 | 2006-11-22 | 调节门离子通道用组合物和方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US7718641B2 (zh) |
EP (1) | EP1957486A4 (zh) |
JP (1) | JP2009516712A (zh) |
KR (1) | KR20080070749A (zh) |
CN (1) | CN101346375B (zh) |
AU (1) | AU2006317545B2 (zh) |
BR (1) | BRPI0618863A2 (zh) |
CA (1) | CA2630617C (zh) |
WO (1) | WO2007059608A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103732583A (zh) * | 2011-06-17 | 2014-04-16 | 葛兰素史密斯克莱知识产权(第2号)有限公司 | Trpv4拮抗剂 |
CN105492423A (zh) * | 2013-08-29 | 2016-04-13 | 株式会社大熊制药 | 四氢环戊并吡咯衍生物及用于制备其的方法 |
CN109364248A (zh) * | 2018-10-16 | 2019-02-22 | 哈尔滨医科大学 | ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4910500A (en) * | 1999-05-19 | 2000-12-12 | Neurosearch A/S | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders |
US8377691B2 (en) * | 2006-01-26 | 2013-02-19 | Integral Molecular, Inc. | Lipoparticles comprising ion channels, methods of making and using the same |
EP2043650A2 (en) | 2006-07-14 | 2009-04-08 | Medical Research Council | Treatment for demyelinating disease |
WO2008144931A1 (en) * | 2007-05-30 | 2008-12-04 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
EP2288922B1 (en) * | 2008-05-08 | 2016-08-17 | University of Utah Research Foundation | Sensory receptors for chronic fatigue and pain and uses thereof |
AU2009332651A1 (en) * | 2008-12-26 | 2011-12-01 | Glenmark Pharmaceuticals, S.A. | Fused imidazole derivatives as TRPV3 antagonist |
US9211313B2 (en) * | 2011-01-14 | 2015-12-15 | The Research Foundation Of State University Of New York | Methods and compound to inhibit Ca2+ permeable cation conductance |
JP5971657B2 (ja) | 2011-04-20 | 2016-08-17 | 塩野義製薬株式会社 | Trpv4阻害活性を有する芳香族複素環誘導体 |
US9499533B2 (en) | 2012-03-27 | 2016-11-22 | Shionogi & Co., Ltd. | Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity |
WO2015021988A1 (en) | 2013-08-12 | 2015-02-19 | Aros Pharma Aps | Pyrrolo-isoquinoline compounds for treatment of pain associated with interstitial cystitis/bladder pain syndrome |
JPWO2015046193A1 (ja) | 2013-09-25 | 2017-03-09 | 塩野義製薬株式会社 | Trpv4阻害活性を有する芳香族複素環式アミン誘導体 |
WO2018151240A1 (ja) * | 2017-02-17 | 2018-08-23 | 第一三共株式会社 | 3,6,7,8-テトラヒドロシクロペンタ[e]インドール化合物 |
WO2018151239A1 (ja) * | 2017-02-17 | 2018-08-23 | 第一三共株式会社 | 3,6-ジヒドロ-2H-フロ[2,3-e]インドール化合物 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9204914A (es) | 1991-08-28 | 1993-07-01 | Frank Watjen | Nuevos derivados de isatinoxima, metodo para su preparacion y composicion farmaceutica que los comprende. |
EP0664807B1 (en) | 1992-10-13 | 1997-09-10 | Warner-Lambert Company | Quinoxalinedione derivatives as eaa antagonists |
US5843945A (en) | 1993-05-13 | 1998-12-01 | Neurosearch A/S | AMPA antagonists and a method of treatment |
JP3439215B2 (ja) * | 1993-05-13 | 2003-08-25 | ノイロサーチ アクティーゼルスカブ | Ampa拮抗薬およびそれを用いての治療方法 |
DK81593D0 (da) | 1993-07-07 | 1993-07-07 | Neurosearch As | Nye isatinoximderivater, deres fremstilling og anvendelse |
ATE188701T1 (de) | 1994-09-14 | 2000-01-15 | Neurosearch As | Kondensierte indole und chinoxalinderivate, ihre herstellung und verwendung als glutamatantagonisten |
US5917053A (en) | 1994-09-14 | 1999-06-29 | Neurosearch A/S | Indole-2,3-dione-3-oxime derivatives, their preparation and use |
UA54403C2 (uk) | 1996-10-01 | 2003-03-17 | Н'Юросерч А/С | Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму |
DE69922936T2 (de) | 1998-03-31 | 2005-12-08 | Neurosearch A/S | Verwendung von indol-2,3-dione-3-oximderivate als ampa-antagonisten |
ATE229954T1 (de) | 1998-06-12 | 2003-01-15 | Sod Conseils Rech Applic | Betacarbolinverbindungen |
AU4910500A (en) * | 1999-05-19 | 2000-12-12 | Neurosearch A/S | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders |
WO2001055110A1 (en) | 2000-01-24 | 2001-08-02 | Neurosearch A/S | Isatine derivatives with neurotrophic activity |
CA2311483A1 (en) * | 2000-06-12 | 2001-12-12 | Gregory N Beatch | IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF |
US7632948B2 (en) | 2002-08-22 | 2009-12-15 | Neurosearch A/S | Method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives |
CL2004000409A1 (es) | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
CN1894222A (zh) | 2003-08-05 | 2007-01-10 | 沃泰克斯药物股份有限公司 | 作为电压门控离子通道抑制剂的稠合嘧啶化合物 |
TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
-
2006
- 2006-11-22 CN CN2006800440109A patent/CN101346375B/zh not_active Expired - Fee Related
- 2006-11-22 WO PCT/CA2006/001897 patent/WO2007059608A1/en active Application Filing
- 2006-11-22 AU AU2006317545A patent/AU2006317545B2/en not_active Ceased
- 2006-11-22 JP JP2008541558A patent/JP2009516712A/ja active Pending
- 2006-11-22 KR KR1020087014653A patent/KR20080070749A/ko not_active Application Discontinuation
- 2006-11-22 BR BRPI0618863A patent/BRPI0618863A2/pt not_active IP Right Cessation
- 2006-11-22 EP EP06804755A patent/EP1957486A4/en not_active Withdrawn
- 2006-11-22 CA CA2630617A patent/CA2630617C/en not_active Expired - Fee Related
- 2006-11-22 US US11/603,946 patent/US7718641B2/en not_active Expired - Fee Related
-
2010
- 2010-04-12 US US12/758,250 patent/US20100197721A1/en not_active Abandoned
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103732583A (zh) * | 2011-06-17 | 2014-04-16 | 葛兰素史密斯克莱知识产权(第2号)有限公司 | Trpv4拮抗剂 |
CN103732583B (zh) * | 2011-06-17 | 2015-12-23 | 葛兰素史密斯克莱知识产权(第2号)有限公司 | Trpv4拮抗剂 |
CN105492423A (zh) * | 2013-08-29 | 2016-04-13 | 株式会社大熊制药 | 四氢环戊并吡咯衍生物及用于制备其的方法 |
CN105492423B (zh) * | 2013-08-29 | 2018-04-06 | 株式会社大熊制药 | 四氢环戊并吡咯衍生物及用于制备其的方法 |
CN109364248A (zh) * | 2018-10-16 | 2019-02-22 | 哈尔滨医科大学 | ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用 |
CN109364248B (zh) * | 2018-10-16 | 2021-05-18 | 哈尔滨医科大学 | ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用 |
Also Published As
Publication number | Publication date |
---|---|
EP1957486A4 (en) | 2009-11-11 |
AU2006317545A1 (en) | 2007-05-31 |
JP2009516712A (ja) | 2009-04-23 |
WO2007059608A1 (en) | 2007-05-31 |
AU2006317545B2 (en) | 2012-04-12 |
US7718641B2 (en) | 2010-05-18 |
US20070191418A1 (en) | 2007-08-16 |
CA2630617C (en) | 2014-03-25 |
CN101346375B (zh) | 2013-04-10 |
BRPI0618863A2 (pt) | 2016-09-13 |
US20100197721A1 (en) | 2010-08-05 |
EP1957486A1 (en) | 2008-08-20 |
KR20080070749A (ko) | 2008-07-30 |
CA2630617A1 (en) | 2007-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101346375B (zh) | 调节门离子通道用组合物和方法 | |
CN101360738A (zh) | 调节门控离子通道的组合物和方法 | |
US20080004306A1 (en) | Compositions and methods for modulating gated ion channels | |
ES2857549T3 (es) | Ligandos de receptores de opioides y métodos para utilizar y obtener los mismos | |
TW202045477A (zh) | 用於治療腦機能障礙的氮呯-吲哚及其他雜環 | |
JP5869484B2 (ja) | 架橋複素環化合物およびその使用 | |
CN102341380A (zh) | 布美他尼、呋塞米、吡咯他尼、佐塞米和托拉塞米类似物、组合物和使用方法 | |
EP1276720B1 (de) | 2-acyl-indolderivate und deren verwendung als antitumormittel | |
US20070004680A1 (en) | Compositions and methods for modulating gated ion channels | |
CN102548986A (zh) | 氨基吡咯烷酮衍生物及其用途 | |
KR20100024951A (ko) | 세포를 자극하기 위한 방법 및 조성물 | |
CN101305002A (zh) | 调节神经营养蛋白介导的活性的方法 | |
BRPI0805826B1 (pt) | compostos espiro-substituídos, composição farmacêutica e uso | |
CN105358559A (zh) | 吡咯并吡啶或吡唑并吡啶衍生物 | |
RU2191776C2 (ru) | Эрголиновые производные, способ их получения, фармацевтическая композиция | |
CN101010297A (zh) | N-(1h-吲哚基)-1h-吲哚-2-羧酰胺衍生物,它们的制备方法和药用用途 | |
CN105611930A (zh) | 作为非凋亡调控性细胞死亡抑制剂的螺环喹喔啉衍生物 | |
US20080021034A1 (en) | Compositions and methods for modulating gated ion channels | |
US20090246134A1 (en) | Compositions and methods for modulating gated ion channels | |
US20080004272A1 (en) | Compositions and methods for modulating gated ion channels | |
CN110483525A (zh) | 用于治疗智力残疾的mglu2/3拮抗剂 | |
US20080262019A1 (en) | Optical Isomers of (+) and (-)-Trans-2,3,4,4A,5,9B-Hexahydro-2,8-Dimethyl-1H-Pyrido[4,3-B] Indole | |
JPH11510159A (ja) | 抗けいれん剤としての未置換および置換n−(ピロール−1−イル)ピリジンアミンの使用 | |
JPH04173777A (ja) | メラトニン類似体 | |
MX2008007889A (en) | Compositions and methods for modulating gated ion channels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ALLOS PHARMACEUTICAL INC. Free format text: FORMER OWNER: PAINCEPTOR PHARMA CORP. Effective date: 20110624 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: QUEBEC, CANADA TO: COPENHAGEN, DENMARK |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110624 Address after: Copenhagen Applicant after: Painceptor Pharma Corp. Address before: Quebec Applicant before: Painceptor Pharma Corp. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130410 Termination date: 20151122 |
|
EXPY | Termination of patent right or utility model |